ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Liquidity and Going Concern (Details) $ in Thousands, € in Millions			1 Months Ended	3 Months Ended
	Jan. 03, 2023 USD ($)	Jan. 03, 2023 EUR (€)	Jan. 31, 2023 USD ($)	Mar. 31, 2024 USD ($)	Mar. 31, 2023 USD ($)	Dec. 31, 2023 USD ($)
Cash and cash equivalents
Exercise of common warrants				$ 9,025
Net loss				(83,938)	$ (10,137)
Accumulated deficit				(552,524)		$ (468,586)
Cash and cash equivalents				$ 146,484		$ 49,898
Substantial Doubt about Going Concern, within One Year				false
Advanz Pharma | License and Supply Agreement
Cash and cash equivalents
Upfront payment received	$ 10,700	€ 10.0	$ 10,700
Leerink ATM Agreement
Cash and cash equivalents
Proceeds from issuance of shares and warrants and warrant exercises, net				$ 113,800